Nanjing Vazyme Biotech Co., Ltd.
SSE:688105.SS
22.71 (CNY) • At close June 13, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,377.898 | 1,285.988 | 3,568.985 | 1,868.627 | 1,564.454 | 268.38 | 170.805 | 112.372 |
| Cost of Revenue
| 414.357 | 514.886 | 1,110.511 | 350.848 | 133.632 | 42.085 | 29.844 | 22.378 |
| Gross Profit
| 963.542 | 771.102 | 2,458.474 | 1,517.78 | 1,430.822 | 226.295 | 140.961 | 89.994 |
| Gross Profit Ratio
| 0.699 | 0.6 | 0.689 | 0.812 | 0.915 | 0.843 | 0.825 | 0.801 |
| Reseach & Development Expenses
| 300.394 | 338.616 | 396.107 | 230.322 | 125.533 | 62.297 | 53.005 | 26.28 |
| General & Administrative Expenses
| 58.935 | 55.871 | 105.131 | 85.755 | 53.626 | 18.071 | 12.316 | 11.942 |
| Selling & Marketing Expenses
| 186.336 | 472.687 | 522.402 | 319.467 | 187.726 | 96.584 | 64.638 | 40.152 |
| SG&A
| 245.271 | 528.557 | 627.533 | 405.222 | 241.352 | 114.654 | 76.954 | 52.093 |
| Other Expenses
| 479.27 | 4.109 | 197.863 | 85.821 | 41.233 | 21.98 | -0.111 | -0.056 |
| Operating Expenses
| 1,024.935 | 871.282 | 1,221.503 | 721.365 | 408.118 | 198.931 | 137.519 | 90.162 |
| Operating Income
| -61.393 | -100.18 | 1,198.466 | 771.138 | 973.016 | 24.319 | 0.526 | 0.005 |
| Operating Income Ratio
| -0.045 | -0.078 | 0.336 | 0.413 | 0.622 | 0.091 | 0.003 | 0 |
| Total Other Income Expenses Net
| 3.142 | -15.534 | -108.104 | -6.693 | -13.757 | 0.05 | -0.111 | 0 |
| Income Before Tax
| -58.251 | -115.714 | 609.39 | 764.445 | 959.258 | 24.369 | 0.416 | 0.005 |
| Income Before Tax Ratio
| -0.042 | -0.09 | 0.171 | 0.409 | 0.613 | 0.091 | 0.002 | 0 |
| Income Tax Expense
| -38.629 | -42.852 | 15.883 | 86.155 | 137.533 | -1.426 | -0.623 | -3.64 |
| Net Income
| -18.094 | -70.956 | 594.246 | 678.29 | 821.725 | 25.795 | 1.039 | 3.645 |
| Net Income Ratio
| -0.013 | -0.055 | 0.167 | 0.363 | 0.525 | 0.096 | 0.006 | 0.032 |
| EPS
| -0.046 | -0.18 | 1.49 | 1.7 | 2.05 | 0.065 | 0.003 | 0.01 |
| EPS Diluted
| -0.046 | -0.18 | 1.49 | 1.7 | 2.05 | 0.065 | 0.003 | 0.01 |
| EBITDA
| 121.513 | 156.125 | 841.804 | 853.116 | 983.887 | 38.377 | 8.768 | 2.919 |
| EBITDA Ratio
| 0.088 | 0.121 | 0.236 | 0.457 | 0.629 | 0.143 | 0.051 | 0.026 |